Not a day goes by without news of another advance in steering stem cells, and the cells derived from them, toward therapies for treating human disorders. For example, last month StemCells, Inc., a Palo Alto biotechnology firm, announced that it has joined forces with clinicians at Oregon Health and Science University for an FDA-approved Phase I clinical trial to transplant neural stem cells purified from human fetal brain tissue into the brains of infants with Batten's disease. The hope is that the transplanted cells will produce the lysosomal enzyme that is missing in this fatal disease. "We're all looking for a sound success where the delivery of cells makes a difference. It would be enormously encouraging," says George Daley, a stem cell researcher at Harvard Medical School.
The overall vision for cell-based therapies, also called regenerative medicine, seems deceptively simple: Use healthy living cells to replace diseased, dying, or missing cells or tissues. One approach is to obtain sufficient numbers of a specific cell type derived from fetal or adult human stem cells, or from human embryonic stem cells, and then transplant an appropriate "dose" of these cells into the patient's body in the correct location. As researchers are discovering, however, turning living cells into transplantable therapies is a complex multistep process.
The FDA's Center for Biologics Evaluation and Research (CBER) is responsible for overseeing therapeutics composed of human cells, tissues, and cellular and tissuebased products-or HCT/Ps. So far only one product, Carticel, has been licensed, which industry analysts say clearly indicates just how young the regenerative medicine field actually is and how many challenges it faces. Carticel, manufactured by Genzyme, is an autologous cell therapy for repairing injured knee cartilage. It was approved by the FDA in 1997 and passed its 10,000 th patient milestone in 2004. Chondrocytes from the patient's healthy cartilage are obtained by biopsy and cultured in the laboratory to expand the cell population, which is then implanted into the patient's injured knee. Several tissue-engineered products, primarily for skin repair, have been approved by another section of the FDA, the Center for Devices and Radiological Health. Because engineered products often combine a biological product with a medical device, from a regulation point of view, they are considered separately from products composed purely of cells.
Fashioning a cell therapy that works effectively in the body may require more R&D than is required for making drugs. "Since these products contain living cells, a number of factors contribute to the challenges of manufacturing and [FDA] approval," noted FDA public affairs specialist Paul Richards in an email, "including the potential for adventitious agent contamination, the need for aseptic processing, the inability to 'sterilize' the final product and assurance they are free from infectious diseases." Distribution of these products can also be a challenge, says Richards, due to their short shelf life and the need to ensure that they remain genetically stable, that is, that they do not acquire mutations.
That there is only one FDAapproved cell product on the market does not reflect the actual number of cell therapies available because approval is not required for cell therapies "that are minimally manipulated, labeled or advertised for homologous use only, and not combined with a drug or device," according to FDA specifications. A surgeon who takes bone marrow cells from a patient's hip bone and immediately puts them back into the same patient's bloodstream does not have to pause for a multi-year review process. However, if cells, whether autologous (from the patient) or allogeneic (from a donor), are cultured for twenty-four hours or longer-that is, manipulated-then FDA oversight is required. (Oversight of bone marrow transplantation, as well as whole organ transplants, falls under the purview of the Health Resources Services Administration and not the FDA.)
For the many cell therapies currently in the R&D pipeline that are more than minimally manipulated, their developers must overcome numerous manufacturing hurdles if their product is to pass FDA muster. Simply knowing which type of cell will work best for treating a particular disorder can take several years to test. For instance, there are as many as twelve different types of cells under investigation for treating cardiovascular disease, according to Robert Deans, vice president of regenerative medicine at Athersys,
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Inc., a Cleveland-based biotech company. They range from stem and progenitor cells derived from umbilical cord blood, bone marrow, blood vessels, adipose tissue, and the heart itself to human embryonic stem cells that have the potential to generate the appropriate cell type. Athersys, together with physicians from the Cleveland Clinic, has its sights set on using a mesenchymal stem cell from adult bone marrow (first identified by Catherine Verfaillie in 1999) to treat acute myocardial infarction. The biotech company expects to soon file an IND (investigational new drug application) with the FDA for their product "MultiStem," the first step on the path to a Phase I clinical trial.
The technology of cell selectionthe ability to isolate the exact type of cell needed in sufficient quantities for an effective dose-has proved problematic for potential cell therapies. Flow cytometry accurately sorts cells into different populations but is slow and uses an aerosol phase that could expose cells to contaminants in the air. "Every mouse paper you read probably has used an optical cell sorter, because that's the most precise way of selecting cells," observes John Gilbert, CEO of Cytonome, a Boston company that is designing an optical sorter with no aerosol phase. "But if you want to move to humans, you've got a problem-safety and speed." Although Cytonome is "still in stealth mode," Gilbert says his company's machine "is an optical sorter that has no aerosol phase-its fluidics are in a closed disposable cartridge-and it's fast enough to make a human cell dose."
The next challenge is how to deliver cell therapies to the patient. For example, should cell therapies for repair of heart tissue be routed through the arteries or veins, or injected straight into heart tissue? Keith March at the Indiana University School of Medicine, who studies cardiovascular repair in a pig animal model, says "We have found that delivery devices and methods vary greatly in their ability to disperse cells in the heart, as well as in the efficiency and consistency of cell placement. It is therefore critical to understand and refine delivery techniques as one is developing therapeutic cells." Magnetic resonance imaging (MRI) is now being applied to track the delivery of magnetically labeled cells after transplant to ensure that they reach their destination and do not wander into surrounding tissues. For example, a recent Nature Biotechnology paper reported magnetic resonance tracking of a dendritic cell vaccine injected into the lymph nodes of eight patients with melanoma. The autologous dendritic cells derived from the patient were loaded with tumor antigen and iron oxide particles in the laboratory prior to injection. MRI revealed that in four patients, the dendritic cells ended up not in the lymph nodes but in the surrounding fat, which may explain the limited effect of dendritic cell vaccines in clinical trials. The Netherlands, China, and other countries have already adopted magnetic resonance tracking in patients. However, it may be one to three more years before the FDA approves an IND application for magnetic resonance tracking in the United States, says Joseph Frank, chief of the NIH's Experimental Neuroimaging Section and a pioneer of the technology.
Even when the biological and technical hurdles are overcome, there is still the regulatory gauntlet to get through. Since 1993, the FDA has been modernizing its regulations to keep up with the research community's growing interest in treating patients with cell-and tissue-based products. Addressing the FDA's concerns regarding the development of stem cell-based products, Darin Weber, former chief of the FDA's cell therapies branch and currently with The Biologics Consulting Group, advises "You want to know your product better than anyone in the world." A thorough understanding of what your cells do in a dish, an animal, and a human will help answer the questions the FDA is inevitably going to ask you about your product, questions like: Where, specifically, will the cells be placed, and if they migrate, where will they go? How well do they integrate into the host, and what is the extent of their functional activity? Safety studies, says Weber, should address dosing issues, delivery techniques, immunosuppression regimens, and potential serious side effects, including the cells' potential to form tumors.
Whether researchers are or aren't manipulating cells, they should be attentive to three new key FDA rules. These additions are intended to strengthen the FDA's monitoring of cells and tissues destined for therapeutic application "while minimizing regulatory burden," according to CBER. The first rule, which became fully effective in January '04, requires any establishment that uses HCT/Ps to register with the FDA and list their manufactured products. The second, "donor eligibility," helps to ensure that tissues meant for transplant come from individuals who are free of disease, with an emphasis on communicable diseases. The third rule-which, along with the "donor eligibility" rule, took effect in May last year-underscores good tissue practice (GTP) and requires researchers to follow specific measures that guard against tissue contamination. "Stem-cell based therapies provide regulatory challenges due to their intrinsic biologic properties, namely, their robust capacity for self-renewal and replication and their ability to differentiate into a variety of tissue types," said Chris Middendorf, Chief of the FDA's Consumer Affairs Branch, in an email. Thus, although preclinical proof-of-concept and toxicological assessment testing for cell-based therapies has much in common with testing for drug approval, "the type and extent of preclinical testing expected may vary depending on perceived risks to the patient posed by the fundamental biology of a cellular therapy, including stem cells…. It is FDA's intention that the extent of regulatory oversight be commensurate with the potential risk posed by the product."
When it comes to approaching the FDA for INDs for cell therapies, the action is principally at the level of small and medium-sized biotech companies, with much less participation by big pharma. This is not altogether surprising, suggests Peter Mountford, CEO of Stem Cell Sciences-a twelve-year-old biotech company that aims to generate neural cell types from human embryonic stem cells to treat Parkinson's disease and other disorders. "Really, biotech needs to be coordinating this project," of growing cells and scaling up their numbers for therapies, says Mountford. "Big pharma isn't going to do it, because they are small molecule companies, and that's their focus. And it's also ethically very sensitive for them-they are very concerned about public reactions. If a large pharma was to announce that they had entered the embryonic stem cell field, it could knock one percent off their market capitalization; that's a very expensive announcement. So it's not for the pharmaceutical industry-although they will buy into the business opportunity when it's more mature. It's truly a biotechbased initiative."
"By and large, big pharma is built on pills and injectibles, and hasn't liked the stem cell model," points out Steven Burrill, CEO of San Francisco-based Burrill and Company, a life sciences firm with ties to venture capital and merchant banking. Burrill foresees a time, nevertheless, when cell therapies will "be an exciting and explosive part of the medical industry," drawing the keen interest of both venture capital and major pharmaceutical companies. Within ten years, he estimates, such interest will begin "perking up," as more and more cell therapies prove themselves.
Even though the majority of cell therapies are being created in the academic setting, in Mountford's view, academic researchers shouldn't necessarily coordinate the scaling up of cell therapies as their place is at the cutting edge of basic research. A current conundrum, notes Darin Weber, is to what extent scientific results from academic labs can be translated into commercial products. Even if they spin off into biotech ventures, they may not be commercially lucrative enough to turn the heads of big pharma. There are, nonetheless, "many companies in the traditional pharmaceuticals-both drug and medical devices-who are investing cautiously in small biotech behind the scenes, hoping that a few actually come to fruition," says Weber.
To date little venture capital has flowed into the stem cell therapeutics field. In Peter Mountford's opinion, venture capitalists tend to have the misconception that stem cell therapy is as risky as gene therapy, which investors shied away from after the death of a patient in 1999. "Gene therapy," observes Mountford "was a whole new concept that was developed to do something that has no real precedent in normal biology": using viruses to deliver genes into cells. Cell-based therapy is different as it "reproduces what the body does normally."
Pfizer, a pharma giant that "is committed to small molecules and not developing any cell-based therapies," says John Hambor with Pfizer Global Research and Development, has been studying mouse embryonic stem cells for more than fifteen years for other reasons. Inducing these cells to differentiate into dopaminergic, serotonergic, or other types of neurons could provide a renewable source of nerve cells for testing new small-molecule drugs for treating neurological diseases such as Parkinson's and schizophrenia. Some onlookers believe that using stem cells for testing new drugs has the potential to wind up a bigger business than using stem cells as therapies. "Stem cells represent an important new source of assays for drug development," observes George Daley, "and in the near term are likely to prove more valuable as tools for drug research rather than therapeutic entities themselves. Until cells can be mass produced as readily and cheaply as small molecules, and used off-the-shelf without having to be customized to individual patients, big pharma will continue to focus on what it does best, making small molecule drugs."
Pharmaceutical companies, meanwhile, are expected to keep adding to an expanding group of manufactured drugs that beneficially trigger the proliferation of stem and progenitor cells in the body. This "endogenous" approach, exemplified by the growth factors erythropoietin and thrombopoietin (which stimulate production of red blood cells and platelets, respectively), handily avoids all of the difficulties associated with transplanting cells. But activating cells in the body to do medicine's bidding requires its own set of complex maneuvers.
Clearly, stem cells and the cells derived from them have great potential to serve medicine-from therapies, to drug testing, to teaching us more about the body's biology. With the cache of FDA-approved new drugs having fallen from over 50 in 1996 to 20 in 2005, according to a New York Times report, the vision of what cell-based medicines might achieve has injected optimism into the difficult search for new ways to treat human disease.
